NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
NSC23005 sodium (Compound 40) is a novel class of INK4C (p18INK4C or p18) small molecule inhibitor (p18SMIs), which is initially found by in silico 3D screening. NSC23005 sodium shows the most potent bioactivity in hematopoietic stem cells (HSCs) expansion (ED50=5.21 nM). Notably, NSC23005 sodium does not show significant cytotoxicity toward 32D cells or HSCs, nor does it augment leukemia cell proliferation. NSC23005 sodium (ED50=5.21 nM), shows no activity in promoting the proliferation of leukemia cells[1].
NSC23005 sodium selectively promote HSCs division by inhibiting p18, thereby activating CDK4/6. NSC23005 sodium is a novel and effective p18 inhibitor in promoting HSCs expansion in both murine and human models[1].
References:
[1]. Xie XQ, et al. Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion. Sci Rep. 2015 Dec 18;5:18115.